Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.
Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, D'Hondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F.
Bregni G, et al. Among authors: demetter p.
Acta Oncol. 2021 Apr;60(4):549-553. doi: 10.1080/0284186X.2020.1871067. Epub 2021 Jan 13.
Acta Oncol. 2021.
PMID: 33435735
Clinical Trial.
No abstract available.